 |
42 Diseases |  |
114 Trials |
|
114 Trials |  |
1648 News |  |
| «12...1920212223242526272829...3031» |
- pegylated liposomal doxorubicin / Generic mfg., nintedanib / Generic mfg.
Phase classification, Combination therapy: Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer (clinicaltrials.gov) - Aug 8, 2016
P1, N=11, Terminated, Sponsor: Hoosier Cancer Research Network
Phase classification: P1/2 --> P1
- pegylated liposomal doxorubicin / Generic mfg., capecitabine / Generic mfg.
Trial primary completion date: Testing the Effectiveness of Henna on Managing PPE (clinicaltrials.gov) - Jul 29, 2016
P=N/A, N=80, Recruiting, Sponsor: Cyprus University of Technology
Phase classification: P1/2 --> P1 Trial primary completion date: Sep 2016 --> Dec 2016
- Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, veliparib (ABT-888) / AbbVie
Enrollment closed, PARP Biomarker, Metastases: Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer (clinicaltrials.gov) - Jul 26, 2016
P1, N=58, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2016 --> Dec 2016 Recruiting --> Active, not recruiting
- || motolimod (VTX 2337) / BMS
Trial primary completion date, Combination therapy: VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Jul 23, 2016
P2, N=290, Active, not recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Oct 2016
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date, Metastases: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=48, Recruiting, Sponsor: Advenchen Laboratories, LLC
Trial primary completion date: Jun 2016 --> Oct 2016 Trial primary completion date: Jun 2016 --> Jan 2017
- eprenetapopt (APR-246) / Aprea
Trial primary completion date: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=25, Recruiting, Sponsor: Aprea AB
Trial primary completion date: Jun 2016 --> Jan 2017 Trial primary completion date: Sep 2016 --> Sep 2018
- | Trial completion: Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma (clinicaltrials.gov) - Jul 12, 2016
P1/2, N=91, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Sep 2016 --> Sep 2018 No longer recruiting --> Completed
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment closed: Doxil, Bevacizumab and Temsirolimus Trial (clinicaltrials.gov) - Jul 12, 2016
P1, N=206, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion, Avastin (bevacizumab) / Roche
Enrollment change: Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Jun 27, 2016
P2, N=240, Recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting N=60 --> 240
- anetumab ravtansine (BAY 94-9343) / Bayer
Enrollment open, Combination therapy: Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer (clinicaltrials.gov) - Jun 22, 2016
P1, N=40, Recruiting, Sponsor: Bayer
N=60 --> 240 Not yet recruiting --> Recruiting
- || Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
Enrollment closed: Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON) (clinicaltrials.gov) - Jun 17, 2016
P=N/A, N=101, Active, not recruiting, Sponsor: ARCAGY/ GINECO GROUP
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Elahere (mirvetuximab soravtansine-gynx) / AbbVie
Phase classification, Combination therapy, Metastases: KEYNOTE PN409: Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FR?) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Jun 15, 2016
P1b, N=145, Recruiting, Sponsor: ImmunoGen, Inc.
Recruiting --> Active, not recruiting Phase classification: P1 --> P1b
- |||||| Zybrestat (fosbretabulin) / Oncotelic
Enrollment open: FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer (clinicaltrials.gov) - Jun 15, 2016
P2/3, N=436, Recruiting, Sponsor: OXiGENE
Phase classification: P1 --> P1b Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date: Doxil, Bevacizumab and Temsirolimus Trial (clinicaltrials.gov) - Jun 11, 2016
P1, N=206, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2017 --> Aug 2018
- ||| Elahere (mirvetuximab soravtansine-gynx) / ImmunoGen
Enrollment closed, Metastases: FORWARD I: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov) - Jun 2, 2016
P2, N=247, Active, not recruiting, Sponsor: ImmunoGen, Inc.
Trial primary completion date: Aug 2017 --> Aug 2018 Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment change, Trial suspension: Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma (clinicaltrials.gov) - Jun 1, 2016
P1, N=17, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=40 --> 17 | Recruiting --> Suspended
- Avastin (bevacizumab) / Roche
Trial primary completion date, Monotherapy, IO biomarker, Metastases: Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma (clinicaltrials.gov) - May 23, 2016
P2, N=26, Recruiting, Sponsor: National Cancer Institute (NCI)
N=40 --> 17 | Recruiting --> Suspended Trial primary completion date: Mar 2017 --> Oct 2017
- | Trial completion, Metastases: A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer (clinicaltrials.gov) - May 23, 2016
P1, N=35, Completed, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Mar 2017 --> Oct 2017 Active, not recruiting --> Completed
- pegylated liposomal doxorubicin / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment change: Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer (clinicaltrials.gov) - May 21, 2016
P1, N=7, Active, not recruiting, Sponsor: Heather Greenlee
Active, not recruiting --> Completed N=18 --> 7
- pegylated liposomal doxorubicin / Generic mfg.
Trial primary completion date, BRCA Biomarker, Metastases: Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy (clinicaltrials.gov) - May 12, 2016
P2, N=50, Recruiting, Sponsor: University of Arizona
N=18 --> 7 Trial primary completion date: Nov 2015 --> Sep 2016
- Avastin (bevacizumab) / Roche
Trial primary completion date, Monotherapy, IO biomarker, Metastases: Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma (clinicaltrials.gov) - Apr 27, 2016
P2, N=26, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2015 --> Sep 2016 Trial primary completion date: May 2016 --> Mar 2017
- | anetumab ravtansine (BAY 94-9343) / Bayer
New P1 trial, Combination therapy: Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer (clinicaltrials.gov) - Apr 26, 2016
P1, N=40, Not yet recruiting, Sponsor: Bayer
- | carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Apr 17, 2016
P3, N=3882, Completed, Sponsor: Gynecologic Oncology Group
Trial primary completion date: May 2016 --> Mar 2017 Active, not recruiting --> Completed
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer, Rituxan (rituximab) / Roche
New P2 trial: BV mini CHP: A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Apr 12, 2016
P2, N=24, Not yet recruiting, Sponsor: Patrick Reagan
- || New P3 trial: Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane (clinicaltrials.gov) - Apr 6, 2016
P3, N=241, Completed, Sponsor: Nordic Society for Gynaecologic Oncology
- || motolimod (VTX 2337) / BMS
Trial primary completion date, Combination therapy: VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Mar 31, 2016
P2, N=290, Active, not recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
Active, not recruiting --> Completed Trial primary completion date: Mar 2016 --> Jun 2016
- Targretin oral (bexarotene oral) / ReXceptor
Trial primary completion date, Metastases: Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma (clinicaltrials.gov) - Mar 29, 2016
P2, N=37, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Mar 2016 --> Jun 2016 Trial primary completion date: Sep 2016 --> Sep 2017
- pegylated liposomal doxorubicin / Generic mfg.
Phase classification, Trial initiation date: HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors (clinicaltrials.gov) - Mar 28, 2016
P1, N=14, Not yet recruiting, Sponsor: Theodore Laetsch
Trial primary completion date: Sep 2016 --> Sep 2017 Phase classification: P=N/A --> P1 | Initiation date: Jan 2016 --> Apr 2016
- Adcetris (brentuximab vedotin) / Seagen, Takeda
Enrollment open: Brentuximab for Newly Diagnosed Hodgkin Disease (clinicaltrials.gov) - Mar 24, 2016
P2, N=40, Recruiting, Sponsor: Mitchell Cairo
Phase classification: P=N/A --> P1 | Initiation date: Jan 2016 --> Apr 2016 Not yet recruiting --> Recruiting
- ||| pegylated liposomal doxorubicin / Generic mfg., pomalidomide / Generic mfg.
Clinical: Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 10, 2016
P1/2, N=70, Active, not recruiting, Sponsor: Oncotherapeutics
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Dec 2016
- || Ninlaro (ixazomib) / Takeda
Clinical: Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients (clinicaltrials.gov) - Mar 10, 2016
P1/2, N=60, Recruiting, Sponsor: Oncotherapeutics
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Dec 2016 Trial primary completion date: Aug 2016 --> Dec 2016
- Trial primary completion date: A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer (clinicaltrials.gov) - Mar 5, 2016
P1, N=24, Recruiting, Sponsor: Fox Chase Cancer Center
Trial primary completion date: Aug 2016 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2018
- | pegylated liposomal doxorubicin / Generic mfg., carboplatin / Generic mfg.
Trial completion: Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Feb 27, 2016
P1, N=0, Completed, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Dec 2015 --> Dec 2018 No longer recruiting --> Completed
- Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, Metastases: Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) (clinicaltrials.gov) - Feb 22, 2016
P1/2, N=90, Recruiting, Sponsor: Western Regional Medical Center
No longer recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- Ninlaro (ixazomib) / Takeda
Trial termination: Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia (clinicaltrials.gov) - Feb 12, 2016
P1, N=18, Terminated, Sponsor: Ehab L Atallah
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Terminated; SAE- risk of overall protocol treatment outweighs benefits
- | Mekinist (trametinib) / Novartis
Clinical: Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (clinicaltrials.gov) - Feb 9, 2016
P2/3, N=250, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Terminated; SAE- risk of overall protocol treatment outweighs benefits Suspended --> Recruiting
- | Recentin (cediranib) / AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
BRCA Biomarker, PARP Biomarker: COCOS: Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - Feb 9, 2016
P2/3, N=680, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Not yet recruiting --> Recruiting
- |||||| Recentin (cediranib) / AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment open, BRCA Biomarker, PARP Biomarker: NRG-GY004: Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Feb 9, 2016
P3, N=450, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Mekinist (trametinib) / Novartis
Clinical: Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (clinicaltrials.gov) - Feb 8, 2016
P2/3, N=250, Suspended, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Suspended
- pegylated liposomal doxorubicin / Generic mfg., lapatinib / Generic mfg.
Trial termination, Combination therapy, Metastases: A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer (clinicaltrials.gov) - Feb 2, 2016
P1, N=11, Terminated, Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Recruiting --> Suspended Active, not recruiting --> Terminated; Safety reasons
- |||| Elahere (mirvetuximab soravtansine-gynx) / ImmunoGen
Enrollment open, Metastases: FORWARD I: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov) - Jan 29, 2016
P2, N=247, Recruiting, Sponsor: ImmunoGen, Inc.
Active, not recruiting --> Terminated; Safety reasons Not yet recruiting --> Recruiting
- pegylated liposomal doxorubicin / Generic mfg., capecitabine / Generic mfg.
Trial primary completion date: Testing the Effectiveness of Henna on Managing PPE (clinicaltrials.gov) - Jan 28, 2016
P=N/A, N=80, Recruiting, Sponsor: Cyprus University of Technology
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2015 --> Sep 2016
- Neulasta (pegfilgrastim) / Roche
Trial primary completion date: PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma (clinicaltrials.gov) - Jan 25, 2016
P=N/A, N=70, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Jun 2015 --> Jun 2017
- Trial primary completion date, PARP Biomarker: Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (clinicaltrials.gov) - Jan 17, 2016
P1, N=48, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2015 --> Jun 2017 Trial primary completion date: Aug 2015 --> Aug 2016
- | Recentin (cediranib) / AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
BRCA Biomarker, PARP Biomarker: COCOS: Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - Jan 15, 2016
P2/3, N=680, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2015 --> Aug 2016 Initiation date: Sep 2015 --> Feb 2016
- Avastin (bevacizumab) / Roche
Enrollment open, Metastases: Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative (clinicaltrials.gov) - Jan 15, 2016
P2, N=37, Recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Sep 2015 --> Feb 2016 Not yet recruiting --> Recruiting
- | Recentin (cediranib) / AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
BRCA Biomarker, PARP Biomarker: NRG-GY004: Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Jan 11, 2016
P3, N=450, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: Jun 2015 --> Feb 2016
- |||||| Bavencio (avelumab) / EMD Serono
Enrollment open, Combination therapy, PD(L)-1 Biomarker, IO biomarker: A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) (clinicaltrials.gov) - Jan 7, 2016
P3, N=550, Recruiting, Sponsor: Pfizer
Initiation date: Jun 2015 --> Feb 2016 Not yet recruiting --> Recruiting
- pegylated liposomal doxorubicin / Generic mfg., lapatinib / Generic mfg.
Enrollment closed, Combination therapy, Metastases: A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer (clinicaltrials.gov) - Jan 4, 2016
P1, N=12, Active, not recruiting, Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || guadecitabine (SGI-110) / Otsuka
Trial primary completion date, Combination therapy: SGI-110 in Combination With Carboplatin in Ovarian Cancer (clinicaltrials.gov) - Dec 29, 2015
P1/2, N=116, Active, not recruiting, Sponsor: Astex Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2015 --> Mar 2016